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Background—In idiopathic pulmonary arterial hypertension (IPAH), increased right ventricular (RV) power is required to
maintain cardiac output. For this, RV O2 consumption (MVO2) must increase by augmentation of O2 supply and/or
improvement of mechanical efficiency–ratio of power output to MVO2. In IPAH with overt RV failure, however, there
is evidence that O2 supply (perfusion) reserve is reduced, leaving only increase in either O2 extraction or mechanical
efficiency as compensatory mechanisms. We related RV mechanical efficiency to clinical and hemodynamic parameters
of RV function in patients with IPAH and associated it with glucose metabolism.
Methods and Results—The patients included were in New York Heart Association (NYHA) class II (n8) and class III
(n8). They underwent right heart catheterization, MRI, and H215O-, 15O2-, C15O-, and 18FDG-PET. RV power and O2
supply were similar in both groups (NYHA class II versus class III: 0.540.14 versus 0.470.12 J/s and 0.1090.022
versus 0.1280.026 mL O2/min per gram, respectively). RV O2 extraction was near-significantly lower in NYHA class
II compared with NYHA class III (6317% versus 7516%, respectively, P0.10). As a result, MVO2 was
significantly lower (0.0660.012 versus 0.0920.010 mL O2/min per gram, respectively, P0.006). RV efficiency was
reduced in NYHA class III (13.93.8%) compared with NYHA class II (27.87.6%, P0.001). Septal bowing,
measured by MRI, correlated with RV efficiency (r0.59, P0.020). No relation was found between RV efficiency
and glucose uptake rate. RV mechanical efficiency and ejection fraction were closely related (r0.81, P0.001).
Conclusions—RV failure in IPAH was associated with reduced mechanical efficiency that was partially explained by RV
mechanical dysfunction but not by a metabolic shift. (Circ Heart Fail. 2011;4:700-706.)
Key Words: idiopathic pulmonary arterial hypertension  right ventricular mechanical efficiency
 oxygen supply and consumption  right ventricular failure  positron emission tomography
In idiopathic pulmonary arterial hypertension (IPAH), bothpulmonary vascular resistance and right ventricular (RV)
afterload increase progressively. This causes RV hypertrophy
and may lead to RV failure. To maintain cardiac output
during the increasing afterload in IPAH, sufficient power
output must be generated by the RV, which requires more O2.
Recently, however, Gomez et al1 observed stress-induced
ischemia in the RV wall of a subset of PAH patients with
overt RV failure and suggested an association between RV
ischemia and dysfunction. The same study also suggests that
RV perfusion reserve at rest may be exhausted in severe
PAH, which would restrict the RV in a further adaptive
response. If perfusion reserve is indeed limited, the only
possibility for the RV to meet its energy requirements is to
increase its mechanical efficiency, which is proportional to
the ratio of ventricular power output and myocardial O2
consumption (MVO2). However, unlike left ventricular (LV)
disease and heart failure in which mechanical efficiency is
reduced,2–10 mechanical efficiency in overt RV failure is
unknown.
Clinical Perspective on p 706
Because of the vascular anatomy of the human RV, its
venous pO2 has not been determined invasively. Recently, we
demonstrated that O2 extraction fraction (OEF) of the thick-
ened RV wall in IPAH can be noninvasively measured using
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the spatial resolution of state-of-the-art PET scanners and
15O2 and C15O tracers.11 We also measured RV perfusion,
using H215O-PET next to OEF to calculate RV MVO2.12
The purposes of this study were to (1) determine the
relationship between RV power output and MVO2 in IPAH
patients and (2) relate RV mechanical efficiency to RV
function, using both clinical and functional assessments in
IPAH patients. We also determined whether mechanical RV
dysfunction and RV glucose uptake rate related to the RV
efficiency that was found.
Methods
Patients
Twenty-six patients with IPAH were eligible for study. Five patients
refused to participate and 5 other patients gave consent but were
subsequently withdrawn because of emergence of severe clinical
condition (n2; hemoptysis and endocarditis) or because of unsuc-
cessful cannula placement in the radial or brachial artery (n3). In
total, 16 patients were included, of which 15 patients were on
optimal treatment and diagnosed with IPAH for a median time of 3
years, ranging from 2 months to 7 years. All patients continued
receiving treatment (Table 1). One patient was newly diagnosed with
severe IPAH and included right before start of drug treatment.
Exclusion criteria were known history of coronary artery disease or
diabetes mellitus, atrial fibrillation, and anemia (hemoglobin 0.13
g/mL). Assessment of the World Health Organization’s 1998
adapted New York Heart Association classification was performed
before study participation by the clinicians responsible for the patient
(A.V.N. and A.B.). The protocol was approved by the Medical Ethics
Review Committee of VU University Medical Center. Each patient
gave written informed consent before study. Y.Y.W. and G.R.
analyzed the images blinded for patient’s clinical state.
Study Design
All patients underwent right heart catheterization (RHC), cardiac
MRI (cMRI), and PET that consisted of 3 consecutive scans using
H215O, 15O2, and C15O to measure myocardial perfusion or blood
flow (MBF), OEF and MVO2 and fractional blood volume, respec-
tively (Figure 1). 15O-PET scans were performed 2 hours after a light
breakfast. One day after the 15O-PET scans, an 18FDG scan was
performed to quantify myocardial glucose uptake rate (online-only
Data Supplement Figure I, A and B). When possible, RHC, cMRI,
and PET studies were performed within 1 week of each other. In 3
subjects, for logistical or personal reasons, the interval between RHC
and PET was 20–55 days and between cMRI and PET, 20–36 days.
Because these patients had stable IPAH under drug treatment, that is,
less than 10% change in 6-minute walk distance over 6 months
before inclusion (53%) and no change in medical therapy or
NYHA class, the interval was considered acceptable.
PET Imaging Protocol
Patients received a cannula in the radial or brachial artery for blood
sampling.
Data Acquisition
The protocol for cardiac H215O and C15O scans has been described
previously.12 Briefly, scans were performed in 2D acquisition mode,
using an ECAT EXACT HR scanner (Siemens/CTI, Knoxville,
TN). After a transmission scan used to correct all subsequent scans
for tissue attenuation, subjects underwent 3 consecutive scans, as
shown in Figure 1. First, a dynamic emission scan (10 minutes, 40
frames with progressive increase in duration) was started simulta-
neously with injection of 1100 MBq H215O. A second identical
emission scan was started at the same time as a bolus inhalation 7
GBq 15O2. During the 15O2 scan, 5 arterial blood samples were
obtained to measure recirculating H215O concentration.11 An addi-
tional arterial sample was drawn to determine arterial O2 content.
Finally, a 6-minute static emission scan was acquired, starting 1
minute after the end of bolus inhalation of 4 GBq C15O gas to allow
imaging of ventricular blood volumes. Approximately 20% of the
administered radioactivity during 15O2 and C15O inhalation is taken
up by the blood.13 During all scans, systemic blood pressure and
peripheral saturation were registered at set intervals. Heart rate and
ECG were monitored continuously.
Image Processing and Data Analysis
All emission data were reconstructed as previously described.12 The
anatomic tissue fraction images, generated by subtracting the C15O
blood pool image from transmission image,14 were resliced into
short-axis images according to anatomic axes of the LV. The same
reslicing parameters were applied to both dynamic H215O and 15O2
images. Using anatomic tissue fraction images, RV wall regions of
Table 1. Patient Characteristics and Hemodynamics
All
NYHA Class II
(n8)
NYHA Class III
(n8) P
Age, y 44.812.8 42.412.4 47.113.6 NS
Female/male 15/1 7/1 8/0 …
Prostacyclin all/single
treatment, n
2/0 4/2
ERA all/single
treatment, n
7/3 3/0
PDE5 all/single
treatment, n
4/1 4/1
6MWD, m 455116 496104 415119 NS
mRAP, mm Hg 97 55 138 0.022
mPAP, mm Hg 5214 4612 5714 NS
Heart rate, bpm 7615 6763 8515 0.012
Stroke volume, mL 6424 8116 4819 0.002
Cardiac output,
L/min
4.61.2 5.30.8 3.91.1 0.009
RV mass, g 10229 9335 11119 NS
RV EDV, mL 16550 15455 17746 NS
RV EF, % 3516 4615 259 0.002
PVR, dyne  s  cm5 697345 504222 890279 0.008
NTproBNP, ng/L 12421777 540669 16932330 NS
SvO2, % 676 713 634 0.002
Arterial O2 content 0.180.02 0.180.02 0.180.01 NS
NYHA indicates New York Heart Association; ERA, endothelin receptor antago-
nist; EDV, end-diastolic volume; EF, ejection fraction; mPAP, mean pulmonary
artery pressure; mRAP, mean right atrial pressure; PDE5, phophodiesterease type
5 inhibitors; PVR, pulmonary vascular resistance; 6MWD, 6-minute walk distance;
RV, right ventricle; and SvO2, mixed venous O2 saturation.
Values are meanSD. P values were tested using t test.
Figure 1. PET protocol time scheme.
C15O scan was initiated 1 minute after
end of C15O inhalation. See text for
explanation.
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interest were defined on basal, distal, and apical planes (Figure 2).
These regions of interest were projected onto dynamic H215O and
15O2 images to generate time-activity curves. Next, volume weighted
averages of basal, distal, and apical time-activity curves were
averaged. MBF was determined from these average time-activity
curves, using the standard single tissue compartment model.15 OEF
was determined from 15O2 scan using dynamic implementation11 of
a previously described model,14 reusing MBF, perfusable tissue
fraction, arterial blood volume, and RV spill-over as determined
from the H215O scan and applying a correction for spill-over from
activity in the pulmonary gas volume as described previously.16 15O2
input function was based on volume of interest drawn in ascending
aorta and corrected for contribution of recirculating water measured
in the arterial blood samples.
Hemodynamic and Oxidative Calculations
A brief description is provided for both RHC and cMRI in the
online-only Data Supplement.
RV ejection fraction (EF) was derived as the ratio of stroke volume
(SV, assessed from aortic flow) to RV end-diastolic volume. RV
postsystolic isovolumic period, which is the time between pulmonary
valve closure and tricuspid valve opening, was determined in the
2-chamber view described previously and corrected for RR time.17 The
interventricular septum plays an important role in RV power generation
in PAH. Therefore, total septal mass, determined by LV mass minus LV
free wall mass, was divided into a right and left septal mass, assuming
that the right and left parts of the septal masses are proportional to their
free wall counterparts. The right septal part was included to the RV wall
mass in the following calculations.
RV Power
Combining hemodynamic data from both RHC and cMRI, the power
(J/s) of the RV was calculated as
(1) PowerHR  mPAP  SV  2.22  106
where HR is heart rate in beats per minute and mPAP is in mm Hg;
SV, in milliliters, was assessed from the difference between LV
end-diastolic volume and end-systolic volume, which was found to
be equally accurate as the forward aortic flow for SV assessment in
IPAH.18 The factor 2.22  106 converts mm Hg  L/min to J/s. Only
mean power output is used in the present study. Saouti et al showed
total power equals 1.23 times mean power19 and thus does not affect
the results qualitatively.
RV Oxygen Consumption and Supply
Regional MVO2 (in mL/min per gram of cardiac tissue) was
calculated for the RV as follows14:
(2) MVO2OEF  MBF  CaO2
where CaO2 is arterial O2 content (mL O2/mL blood).14 Myocardial
O2 supply (mL/min per gram) was calculated as MBFCaO2.
Mechanical efficiency was calculated from the ratio of RV power
output (Eq 1) and MVO2 (Eq 2). As MVO2 in Equation 2 is
calculated per gram, RV mass is included here for calculation of
MVO2 by whole RV. To convert RV MVO2 to units of metabolic
power (J/s), it was multiplied by the caloric equivalent of O2: 1 mL
of O2/min corresponds to about 0.34 J/s, assuming that RV oxidizes
free fatty acid and glucose equally:
(3) Mechanical efficiencyPower/
MVO2  RV mass  0.34100%
Statistical Analysis
All results are expressed as meanSD. The 2 groups (ie, NYHA
classes II and III) were compared using t tests; the nonparametric
Mann–Whitney U test was used where indicated. Pearson correlation
was performed where necessary. All statistics were performed using
Prism 5 for Windows (GraphPad Software, San Diego, CA). P0.05
was considered significant.
Results
Patient characteristics and hemodynamics are summarized in
Table 1; some parameters are also shown in Figure 3. In
accordance with severity of IPAH, NYHA class III patients
had lower SV and cardiac output (CO) (Figure 3A), despite
higher heart rate as compared with NYHA class II. Mean
PAP was near-significantly higher in NYHA class III as
compared with class II (Figure 3B; P0.083, Mann–Whitney
U test). PVR was increased in NYHA class III, whereas RV
mass was similar in the 2 groups. RVEF and SvO2 were lower
in NYHA class III. Six-minute walk distance was not signif-
icantly lower in the severely ill.
PET-derived parameters for the RV per cardiac mass are
shown in Table 2. Both MBF (corrected for RV mass, Figure
3C) and OEF (Figure 3D) were not significantly higher in the
NYHA class III (MBF: P0.088, t test; OEF: P0.105,
Mann–Whitney U test). There was, however, a significantly
higher MVO2 per gram (Table 2). In contrast, RV O2 supply
per gram RV was similar in NYHA class II and class III
patients (Table 2). For total RV, MVO2 was also higher in the
severely ill (Figure 3F), whereas RV power was not signifi-
cantly lower (Figure 3E). This led to a significant reduction of
RV efficiency by 	50% in the NYHA class III patients
compared with the NYHA class II patient group (Figure 3G).
A tight relationship was found between the mechanical
efficiency and RVEF, a hemodynamic index of systolic RV
function parameter (Figure 4, r0.81, P0.001). There
Figure 2. Example of a cardiac MRI and C15O-PET image of a patient with idiopathic pulmonary arterial hypertension (IPAH) with New
York Heart Association class III. Cardiac MRI image of a patient’s heart with severe IPAH at short-axis view, cut at mid level of the
heart (A). C15O-PET image, reconstructed as an attenuation tissue fraction, a so-called “negative image” of the ventricular blood vol-
umes after inhalation of C15O (B). Using this image, the right ventricular (RV) wall was defined, depicted as the marked region in C. The
RV wall regions of base, mid, and apical levels were combined to an RV wall volume. This was then projected onto the dynamic H2
15O
and 15O2 images for quantification RV blood flow and O2 extraction, respectively.
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was also a high correlation between RV efficiency and SvO2
(r0.76, P0.001).
In search for an underlying mechanical cause for the reduced
efficiency, postsystolic isovolumic period was plotted against
the RV efficiency, showing a negative correlation (r0.594,
P0.020, Figure 5). No correlation was found between the RV
myocardial glucose uptake rate and RV efficiency (r0.38;
P0.18, online-only Data Supplement Figure I, C).
Discussion
In the present study, we demonstrate that RV mechanical
efficiency is lower in NYHA class III than in NYHA class II
patients (Figure 3G), indicating a decrease with progression of
IPAH. In addition, the strong relation between RVEF and
mechanical efficiency (Figure 4) stresses the fact that decreasing
mechanical efficiency is a characteristic for deterioration of RV
function in IPAH. The reduced efficiency in NYHA class III
patients is not related to RV power output, because this was
Figure 3. Overview of the determinants of right ventricular (RV) mechanical efficiency. Primary measurements are cardiac output (A)
measured by cardiac MRI, mean pulmonary artery pressure (mean PAP, B) acquired by right heart catheterization, myocardial blood
flow (C) that was measured by H2
15O-PET, and RV O2 extraction fraction (D) obtained by
15O2-PET. RV power (E) is the product of car-
diac output and mean PAP (Equation 1, Methods Section) and myocardial O2 consumption (F) is the product of O2 extraction fraction,
myocardial blood flow and arterial O2 content (Equation 2). Mechanical efficiency (G) is the ratio of power and myocardial O2 consump-
tion (Equation 3). There was a trend toward significant difference for mean PAP (P0.083, Mann–Whitney U test), O2 extraction fraction
(P0.105, Mann–Whitney U test) and myocardial blood flow (P0.088). Each panel shows results for New York Heart Association class
II (left bar) and class III (right bar) patients. **P0.01; ***P0.001.
Table 2. Perfusion and O2 Consumption of Right Ventricle Per
Unit Mass Measured by PET
NYHA Class II
(n8)
NYHA Class III
(n8) P
MBF, mL/min per gram 0.610.15 0.710.16 NS
O2 supply, mL/min per gram 0.1090.022 0.1280.026 NS
MVO2, mL/min per gram 0.0660.012 0.0920.010 0.001
NYHA indicates New York Heart Association; MBF, myocardial blood flow;
and MVO2, myocardial oxygen consumption.
Values are meanSD; P values were tested using t test.
Figure 4. Right ventricular (RV) efficiency as function of RV ejec-
tion fraction. A strong correlation exists between the 2 parame-
ters (see text). Filled circles indicate New York Heart Associa-
tion (NYHA) class II; open circles, NYHA class III patients.
Regression line (thick broken line) and 95% confidence band
(thin dashed lines) are shown.
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similar between the 2 groups (Figure 3E), but NYHA class III
patients had higher MVO2 of both total RV (Figure 3F) and per
unit RV mass (Table 2) as compared with NYHA class II.
To the best of our knowledge, there are no previous data on
human OEF and perfusion of the normal RV to compare with
our patient data. Based on canine studies, normal RV OEF
has been estimated as 45–50%,20,21 indicating that the RV has
a substantially higher O2 extraction reserve than the left heart
(OEF values are 60–80% in healthy men).4,5 Additionally,
Hart et al21 demonstrated that during heavy exercise, RV O2
utilization increases initially by maximizing OEF before
coronary reserve is mobilized. Interestingly, we found a mean
RV OEF of 6917% in our IPAH patients (Figure 3D),
approximating that of normal LV. Our data suggests that in
analogy with the normal (canine) RV during strenuous exercise,
the pressure-overloaded RV in IPAH already has a reduced O2
extraction reserve at rest, and resting O2 demand becomes
predominantly dependent on perfusion. We found similar
MBF in the hypertrophied RV between mild and severe
IPAH. We therefore hypothesize that the dysfunctional RV is
unable to increase its perfusion in severe PAH, and thus O2
supply cannot increase to meet a higher O2 demand (eg,
during physical exercise). RV ischemia is then the result,
which is in accordance with the observation by Gomez et al,
who demonstrated stress-induced RV wall ischemia in IPAH
patients with severe heart failure.1 The high RV OEF that we
found may also increase the risk to develop hypoxia in the
hypertrophied RV cardiomyocytes.
RV power in the NYHA class III group was similar to
NYHA class II (Figure 3E), despite lower SV and CO (Table
1 and Figure 3A), but we must take into account that RV
power is significantly higher compared with the normal RV
(online-only Data Supplement Figure II). Previous studies
also demonstrated that patients with advanced IPAH had
significantly reduced CO but similar mPAP as compared with
mild IPAH.22–24 The RV power that can be calculated from
the data provided in these studies22–24 is also not significantly
lower in the patients with progressive IPAH, which is in
agreement with our data. It follows from the lower CO and
unchanged mPAP that PVR is higher in the NYHA class III
patients (Table 2). Apparently, RV power output cannot be
increased in advanced IPAH to maintain CO and SV, which
is a sign of RV failure. This is further supported by the tight
relationship between RVEF and mechanical efficiency (Fig-
ure 4), which has also been shown in patients with ischemic
LV heart disease.6 Reduced SvO2 is a strong prognostic
determinant in IPAH, as it is associated with a decreased
cardiac output in the severely ill. It is noticeable that RV
efficiency independently correlates well with SvO2, empha-
sizing once more that mechanical efficiency is a strong
indicator for RV function.
Potential Underlying Mechanisms of Mechanical
Inefficiency at the Mechanical and/or
Cardiomyocyte Level
Mechanical dysfunction can be due to tricuspid regurgitation,
septal bowing,25 asynchronous activation,25 and/or diastolic
dysfunction.26 Power output loss caused by tricuspid regur-
gitation, however, was small and did not influence the
mechanical efficiency in our present study (online-only Data
Supplement Table I). In contrast, we did find a weak but
significant inverse relation between prolonged postsystolic
isovolumic period and reduced RV efficiency (Figure 5).
Based on recent insight,17 this prolonged period is related to
the postsystolic RV isovolumetric contraction period rather
than a prolonged diastolic relaxation time, indicating the
presence of abnormal increased RV wall tension in these
patients.25 This prolonged period is visible on echocardiog-
raphy or cMRI as leftward septal bowing after pulmonary
valve closure, increasing RV MVO2 without ejection of
blood. The low correlation coefficient found between this
period and RV efficiency, however, suggests that the reduced
efficiency cannot be explained by this prolonged isovolumic
contraction period alone. Prostacyclin was shown to improve
the right arterioventricular coupling through reduction of
arterial elastance.27 This treatment was more common in the
NYHA class III group (Table 1). Nevertheless, it did not
prevent the reduced RV efficiency in our patient population.
Furthermore, it is possible that myocardial fibrosis contrib-
utes to a reduced mechanical efficiency. Blyth et al found that
patients with a lower RVEF had more myocardial fibrosis
than patients with a preserved RVEF.28
Additional causes for reduced efficiency must be sought at
the cardiomyocyte level in advanced RV failure. Unfortu-
nately, it is not possible to obtain RV cardiac tissue in our
study population for histological analysis of morphological
changes or capillary density. Preclinical pulmonary hyperten-
sion (PH) studies, however, show that RV cardiomyocytes
are enlarged with reduced capillary density.29,30 The oxygen
diffusion distance is increased as the result of these changes,
which may be an underlying cause for reduction in efficiency.
Indeed, we recently showed a similar reduction in mechanical
efficiency in the isolated, hypertrophied RV papillary muscle
obtained from an experimental PH model.31
Chronic heart failure takes place with a metabolic shift
from free fatty acids to glucose oxidation.3,4,8 This shift was
demonstrated also in the hypertrophied RV in experimental
and clinical PAH studies.32–34 In theory, the efficiency should
increase because glucose oxidation yields more energy than
Figure 5. Plot of the postsystolic isovolumic period (PS-IVP),
corrected for RR time (in fraction of heart cycle) against the right
ventricular (RV) mechanical efficiency. Dashed line represents
the best fit to the data. R2 was 0.35. In 1 patient, this period
was not obtained. Filled circles indicate New York Heart Asso-
ciation (NYHA) class II; open circles, NYHA class III patients.
Regression line (thick broken line) and 95% confidence band
(thin dashed lines) are shown.
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fat oxidation per mole of oxygen. However, in heart failure,
the shift to glucose oxidation appears to concur with the
presence of reduced mechanical efficiency, suggesting that
the glucose shift is a secondary phenomenon to the dimin-
ished efficiency. We also measured the glucose metabolism
in our patients and found that the RV glucose uptake rate was
similar in NYHA class II and NYHA class III patients
(P0.18; online-only Data Supplement Figure I, C). The
increased MVO2 to power output in severe IPAH suggests
inefficient O2 utilization by the failing RV as the result of
cellular processes in which O2 is used for processes other than
ATP production for contraction, for example, ion pumps,
protein turnover, mitochondrial uncoupling, or oxygen radi-
cal formation.2,3,5–39 Indeed, local administration of XO
inhibitor, NO-synthase inhibitor or vitamin C (a reactive
oxygen species scavenger) have been shown to ameliorate the
low LV efficiency in cardiomyopathy patients;2,7,39 as well, it
was reported to attenuate RV failure in a PH rat model.40
Future studies on the isolated RV papillary muscle of PH rats
are warranted to test whether these substances also improve
the reduced RV efficiency found in PH.
Our data indicate that clinical judgment, for example,
NYHA class—a well-known prognostic determinant for sur-
vival in PAH—is a reflection of the RV mechanical ineffi-
ciency.23 We hypothesize that there is not only a mere
association between NYHA class and mechanical efficiency
but that RV inefficiency is an underlying factor causing
clinical deterioration and that it plays a central role in RV
failure in IPAH.
Limitations
We acknowledge that the present study lacks a control group.
Unfortunately, the normal RV wall is too thin for accurate
measurements of MBF and OEF, given the spatial resolution
of current PET scanners. Nevertheless, we were able to
include patients with sufficiently different disease severity to
discover the significant correlation between RV efficiency
and RVEF. Ideally, all measurements required for calculation
of mechanical efficiency should be acquired simultaneously.
This was not possible because of the variety of measurement
modalities used. However, only clinically stable IPAH pa-
tients participated in this study, and most measurements were
performed within 1 week. We have chosen to include part of
the septum in the RV myocardial mass. To date, it is not clear
how much it contributes to RV pumping and O2 consumption in
IPAH. We performed calculations of RV efficiency also by
taking either the full septum into account or only the RV free
wall and found qualitatively similar results (online-only Data
Supplement Figure III). Finally, it would be interesting to
compare the RV mechanical efficiency between different PAH
subgroups. Differences in RV mechanical efficiency may be an
underlying factor to explain the differences found in the hemo-
dynamics and prognosis between IPAH patients and patients
with PAH secondary to scleroderma or Eisenmenger syndrome.
Conclusion
RV mechanical efficiency is reduced in severe IPAH compared
with milder stages of the disease process and is only partially
explained by RV mechanical dysfunction, but not by a metabolic
shift to glucose oxidation. The reduction in mechanical effi-
ciency is strongly correlated with RVEF, implying that the
increased O2 use relative to power output is a feature of RV
failure.
Sources of Funding
Dr Vonk-Noordegraaf was supported by The Netherlands Organiza-
tion for Scientific Research (Vidi grant No. 917.96.306).
Disclosures
Dr Vonk-Noordegraaf received speaker’s and advisory board grants
from Actelion and Pfizer and received a speaker’s grant from
GlaxoSmithKline. Dr Boonstra received a speaker’s grant
from Pfizer.
References
1. Gomez A, Bialostozky D, Zajarias A, Santos E, Palomar A, Martinez ML,
Sandoval J. Right ventricular ischemia in patients with primary pulmo-
nary hypertension. J Am Coll Cardiol. 2001;38:1137–1142.
2. Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA,
Marban E, Hare JM. Allopurinol improves myocardial efficiency in
patients with idiopathic dilated cardiomyopathy. Circulation. 2001;104:
2407–2411.
3. Murray AJ, Cole MA, Lygate CA, Carr CA, Stuckey DJ, Little SE,
Neubauer S, Clarke K. Increased mitochondrial uncoupling proteins,
respiratory uncoupling and decreased efficiency in the chronically
infarcted rat heart. J Mol Cell Cardiol. 2008;44:694–700.
4. Laine H, Katoh C, Luotolahti M, Yki-Jarvinen H, Kantola I, Jula A,
Takala TO, Ruotsalainen U, Iida H, Haaparanta M, Nuutila P, Knuuti J.
Myocardial oxygen consumption is unchanged but efficiency is reduced
in patients with essential hypertension and left ventricular hypertrophy.
Circulation. 1999;100:2425–2430.
5. Agostini D, Iida H, Takahashi A, Tamura Y, Henry Amar M, Ono Y.
Regional myocardial metabolic rate of oxygen measured by O2–15 inha-
lation and positron emission tomography in patients with cardiomyopa-
thy. Clin Nucl Med. 2001;26:41–49.
6. Nichols AB, Pearson MH, Sciacca RR, Cannon PJ. Left ventricular
mechanical efficiency in coronary artery disease. J Am Coll Cardiol.
1986;7:270–279.
7. Shinke T, Takaoka H, Takeuchi M, Hata K, Kawai H, Okubo H, Kijima
Y, Murata T, Yokoyama M. Nitric oxide spares myocardial oxygen
consumption through attenuation of contractile response to beta-
adrenergic stimulation in patients with idiopathic dilated cardiomyopathy.
Circulation. 2000;101:1925–1930.
8. Tuunanen H, Engblom E, Naum A, Nagren K, Hesse B, Airaksinen KEJ,
Nuutila P, Iozzo P, Ukkonen H, Opie LH, Knuuti J. Free fatty acid
depletion acutely decreases cardiac work and efficiency in cardiomyo-
pathic heart failure. Circulation. 2006;114:2130–2137.
9. Kim IS, Izawa H, Sobue T, Ishihara H, Somura F, Nishizawa T, Nagata
K, Iwase M, Yokota M. Prognostic value of mechanical efficiency in
ambulatory patients with idiopathic dilated cardiomyopathy in sinus
rhythm. J Am Coll Cardiol. 2002;39:1264–1268.
10. Knaapen P, Germans T, Knuuti J, Paulus WJ, Dijkmans PA, Allaart CP,
Lammertsma AA, Visser FC. Myocardial energetics and efficiency:
current status of the noninvasive approach. Circulation. 2007;115:
918–927.
11. Lubberink M, Wong YY, Raijmakers PGHM, Schuit RC, Luurtsema G,
Boellaard R, Knaapen P, Vonk-Noordegraaf A, Lammertsma AA. Myo-
cardial oxygen extraction fraction measured using bolus inhalation of
15O-oxygen gas and dynamic PET. J Nucl Med. 2011;52:60–66.
12. Knaapen P, van Campen LMC, de Cock CC, Gotte MJW, Visser CA,
Lammertsma AA, Visser FC. Effects of cardiac resynchronization
therapy on myocardial perfusion reserve. Circulation. 2004;110:
646–651.
13. Luurtsema G, Boellaard R, Greuter HNJM, Rijbroek A, Takkenkamp K,
de Geest FGM, Buijs FL, Harry Hendrikse N, Franssen EJF, Van Lingen
A, Lammertsma AA. Pharmaceutical preparation of oxygen-15 labelled
molecular oxygen and carbon monoxide gasses in a hospital setting.
J Clin Pharm Ther. 2010;35:63–69.
14. Iida H, Rhodes CG, Araujo LI, Yamamoto Y, de Silva R, Maseri A, Jones
T. Noninvasive quantification of regional myocardial metabolic rate for
oxygen by use of 15O2 inhalation and positron emission tomography:
Wong et al Inefficient O2 Use by Failing Right Heart in PAH 705
theory, error analysis, and application in humans. Circulation. 1996;94:
792–807.
15. Hermansen F, Rosen SD, Fath-Ordoubadi F, Kooner JS, Clark JC, Camici
PG, Lammertsma AA. Measurement of myocardial blood flow with
oxygen-15 labelled water: comparison of different administration pro-
tocols. Eur J Nucl Med. 1998;25:751–759.
16. Iida H, Rhodes CG, de Silva R, Yamamoto Y, Araujo LI, Maseri A, Jones
T. Myocardial tissue fraction: correction for partial volume effects and
measure of tissue viability. J Nucl Med. 1991;32:2169–2175.
17. Mauritz GJ, Marcus JT, Westerhof N, Postmus PE, Vonk-Noordegraaf A.
Prolonged right ventricular post-systolic isovolumic period in pulmonary
arterial hypertension is not a reflection of diastolic dysfunction. Heart.
2011;97:473–478.
18. Mauritz GJ, Marcus JT, Boonstra A, Postmus PE, Westerhof N, Vonk
Noordegraaf A. Non-invasive stroke volume assessment in patients with
pulmonary arterial hypertension: left-sided data mandatory. J Cardiovasc
Magn Reson. 2008;10:51.
19. Saouti N, Westerhof N, Helderman F, Marcus JT, Boonstra A, Postmus
PE, Vonk-Noordegraaf A. Right ventricular oscillatory power is a
constant fraction of total power irrespective of pulmonary artery pressure.
Am J Respir Crit Care Med. 2010;182:1315–1320.
20. Kusachi S, Nishiyama O, Yasuhara K, Saito D, Haraoka S, Nagashima H.
Right and left ventricular oxygen metabolism in open-chest dogs. Am J
Physiol. 1982;243:H761–H766.
21. Hart BJ, Bian X, Gwirtz PA, Setty S, Downey HF. Right ventricular
oxygen supply/demand balance in exercising dogs. Am J Physiol Heart
Circ Physiol. 2001;281:H823–H830.
22. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS.
Survival in primary pulmonary hypertension with long-term continuous
intravenous prostacyclin. Ann Intern Med. 1994;121:409–415.
23. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, Rainisio M,
Simonneau G. Long-term intravenous epoprostenol infusion in primary
pulmonary hypertension: prognostic factors and survival. J Am Coll
Cardiol. 2002;40:780–788.
24. Rozkovec A, Montanes P, Oakley CM. Factors that influence the outcome
of primary pulmonary hypertension. Br Heart J. 1986;55:449–458.
25. Marcus JT, Gan CT, Zwanenburg JJM, Boonstra A, Allaart CP, Gotte
MJW, Vonk Noordegraaf A. Interventricular mechanical asynchrony in
pulmonary arterial hypertension: left-to-right delay in peak shortening is
related to right ventricular overload and left ventricular underfilling. J Am
Coll Cardiol. 2008;51:750–757.
26. Gan CT-J, Holverda S, Marcus JT, Paulus WJ, Marques KM, Bronzwaer
JGF, Twisk JW, Boonstra A, Postmus PE, Vonk-Noordegraaf A. Right
ventricular diastolic dysfunction and the acute effects of sildenafil in
pulmonary hypertension patients. Chest. 2007;132:11–17.
27. Kerbaul F, Brimioulle S, Rondelet B, Dewachter C, Hubloue I, Naeije R.
How prostacyclin improves cardiac output in right heart failure in con-
junction with pulmonary hypertension. Am J Respir Crit Care Med.
2007;175:846–850.
28. Blyth KG, Groenning BA, Martin TN, Foster JE, Mark PB, Dargie HJ,
Peacock AJ. Contrast enhanced-cardiovascular magnetic resonance
imaging in patients with pulmonary hypertension. Eur Heart J. 2005;26:
1993–1999.
29. Handoko ML, De Man FS, Happe CM, Schalij I, Musters RJP, Westerhof
N, Postmus PE, Paulus WJ, Van Der Laarse WJ, Vonk Noordegraaf A.
Opposite effects of training in rats with stable and progressive pulmonary
hypertension. Circulation. 2009;120:42–49.
30. Mouchaers KTB, Schalij MJ, Versteilen AMG, Hadi AM, Van Nieuw
Amerongen GP, Van Hinsbergh VWM, Postmus PE, Van Der Laarse WJ,
Vonk Noordegraaf A. Endothelin receptor blockade combined with
phosphodiesterase-5 inhibition increases right ventricular mitochondrial
capacity in pulmonary arterial hypertension. Am J Physiol Heart Circ
Physiol. 2009;297:H200–H207.
31. Wong YY, Handoko ML, Mouchaers KTB, De Man FS, Vonk Noor-
degraaf A, Van Der Laarse WJ. Reduced mechanical efficiency of rat
papillary muscle related to degree of hypertrophy of cardiomyocytes.
Am J Physiol Heart Circ Physiol. 2010;298:H1190–H1197.
32. Oikawa M, Kagaya Y, Otani H, Sakuma M, Demachi J, Suzuki J,
Takahashi T, Nawata J, Ido T, Watanabe J, Shirato K. Increased
[18F]fluorodeoxyglucose accumulation in right ventricular free wall in
patients with pulmonary hypertension and the effect of epoprostenol.
J Am Coll Cardiol. 2005;45:1849–1855.
33. Nagaya N, Goto Y, Satoh T, Uematsu M, Hamada S, Kuribayashi S,
Okano Y, Kyotani S, Shimotsu Y, Fukuchi K, Nakanishi N, Takamiya M,
Ishida Y. Impaired regional fatty acid uptake and systolic dysfunction in
hypertrophied right ventricle. J Nucl Med. 1998;39:1676–1680.
34. Piao L, Fang YH, Cadete VJJ, Wietholt C, Urboniene D, Toth PT,
Marsboom G, Zhang HJ, Haber I, Rehman J, Lopaschuk GD, Archer SL.
The inhibition of pyruvate dehydrogenase kinase improves impaired
cardiac function and electrical remodeling in two models of right ven-
tricular hypertrophy: resuscitating the hibernating right ventricle. J Mol
Med. 2010;88:47–60.
35. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin
Invest. 2005;115:500–508.
36. de Jong JW, Schoemaker RG, de Jonge R, Bernocchi P, Keijzer E,
Harrison R, Sharma HS, Ceconi C. Enhanced expression and activity of
xanthine oxidoreductase in the failing heart. J Mol Cell Cardiol. 2000;
32:2083–2089.
37. Farahmand F, Hill MF, Singal PK. Antioxidant and oxidative stress
changes in experimental cor pulmonale. Mol Cell Biochem. 2004;260:
21–29.
38. Nagendran J, Gurtu V, Fu DZ, Dyck JRB, Haromy A, Ross DB, Rebeyka
IM, Michelakis ED. A dynamic and chamber-specific mitochondrial
remodeling in right ventricular hypertrophy can be therapeutically
targeted. J Thorac Cardiovasc Surg. 2008;136:168–178.
39. Shinke T, Shite J, Takaoka H, Hata K, Inoue N, Yoshikawa R,
Matsumoto H, Masai H, Watanabe S, Ozawa T, Otake H, Matsumoto D,
Hirata KI, Yokoyama M. Vitamin C restores the contractile response to
dobutamine and improves myocardial efficiency in patients with heart
failure after anterior myocardial infarction. Am Heart J. 2007;154:
645–648.
40. Redout EM, van der Toorn A, Zuidwijk MJ, van de Kolk CWA, van
Echteld CJA, Musters RJP, van Hardeveld C, Paulus WJ, Simonides WS.
Antioxidant treatment attenuates pulmonary arterial hypertension-
induced heart failure. Am J Physiol Heart Circ Physiol.
2010;298:H1038–H1047.
CLINICAL PERSPECTIVE
The energy metabolism of the heart, as an aerobic organ, is strongly dependent on the myocardial oxygen consumption.
Mechanical efficiency is the power output of the heart relative to the myocardial oxygen consumption. In idiopathic
pulmonary arterial hypertension (IPAH), the hypertrophied right ventricle (RV) must increase its power output to overcome
the elevated pulmonary vascular resistance. It is unknown how the generated RV power is related to RV oxygen usage in
IPAH patients. By means of 15O-PET, we noninvasively measured the oxygen consumption of the hypertrophied RV. We
demonstrate that the New York Heart Association class III IPAH patients with severe RV dysfunction had lower
mechanical efficiency than the patients with milder IPAH. The reduced RV efficiency was not related to RV glucose uptake
(measured by 18FDG-PET) and could only partially be explained by the presence and severity of leftward septal bowing that is
known to contribute to RV mechanical dysfunction in IPAH. RV efficiency was highly related to the RV ejection fraction (as
an objective hemodynamic measure). These findings increase our understanding of RV heart failure secondary to PAH.
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